This article has Open Peer Review reports available.
Effect of topical fluoroquinolones on the expression of matrix metalloproteinases in the cornea
© Reviglio et al; licensee BioMed Central Ltd. 2003
Received: 23 April 2003
Accepted: 06 October 2003
Published: 06 October 2003
Matrix metalloproteinases play an important role in extracellular matrix deposition and degradation. Based on previous clinical observations of corneal perforations during topical fluoroquinolone treatment, we decided to evaluate the comparative effects of various fluoroquinolone eye drops on the expression of matrix metalloproteinases (MMPs) in cornea.
Eighty female Lewis rats were divided into two experimental groups: intact and wounded corneal epithelium. Uniform corneal epithelial defects were created in the right eye with application of 75% alcohol in the center of the tissue for 6 seconds. The treatment groups were tested as follows: 1) Tear drops: carboxymethylcellulose sodium 0.5 % (Refresh, Allergan); 2) Ciprofloxacin 0.3% (Ciloxan, Alcon); 3) Ofloxacin 0.3%(Ocuflox, Allergan); 4) Levofloxacin 0.5%(Quixin, Santen). Eye drops were administered 6 times a day for 48 hours. Rats were sacrificed at 48 hours. Immunohistochemical analysis and zymography were conducted using antibodies specific to MMPs-1, 2, 8 and 9.
MMP-1, MMP-2, MMP-8 and MMP-9 expression were detected at 48 hrs in undebrided corneal epithelium groups treated with the topical fluoroquinolones. No statistical difference was observed in quantitative expression of MMPs among ciprofloxacin 0.3%, ofloxacin 0.3%, levofloxacin 0.5%. When the artificial tear group and the fluoroquinolone groups with corneal epithelial defect were compared, increased expression of MMPs was observed as a result of the wound healing process. However, the fluoroquinolone treated group exhibited high statistically significantly levels of MMPs expression.
Our study provides preliminary evidence that topical application of fluoroquinolone drugs can induce the expression of MMP-1, MMP-2, MMP-8 and MMP-9 in the undebrided corneal epithelium compared to artificial tear eye drops.
Since their introduction in the United States over a decade ago, the quinolone antibacterial agents have become a mainstay in the treatment of serious bacterial infections. The fluoroquinolones are known for their extremely broad spectrum of antibacterial activity.[1, 2] They exert a bactericidal effect by inhibiting bacterial DNA synthesis through interference with the enzymes DNA gyrase and topoisomerase IV. The structural differences of the fluorinated carboxyquinolones commercially available, for topical ophthalmic use, alter their potency as well as their pharmacological profiles. To be clinically useful, antibiotics should be effective with minimal adverse effects. Although fluoroquinolones have been shown to be highly effective antibacterial agents, several clinical studies have reported a fluoroquinolone-induced tendinopathy with bone and articular damage associated with alterations in collagen deposition and chondrocyte function after systematic fluoroquinolone administration. [3–5] Topical fluoroquinolone antibiotics are frequently administered prophylactically in post-surgical care and represent a therapeutic option in the treatment of infectious conjunctivitis and keratitis. These are generally well tolerated and compare favorably with other topical antibiotics in terms of efficacy. However, it is interesting to note that most of the commercial fluoroquinolone ophthalmic solutions contain very low concentrations of the preservatives benzalkonium chloride or edetate disodium (Ciloxan at 0.006%, Ocuflox at 0.05 mg and Quixin at 0.005%) in their formulations. As it is known, much of the reported toxicity has been associated with the presence of certain preservatives in high concentrations (close to 0.1%) which is not the case with the current fluoroquinolone formulations studied. In vivo animal and in vitro studies have also demonstrated that fluoroquinolone agents may adversely affect wound healing by exerting cytotoxic effects on corneal epithelial cells and keratocytes; however, the exact mechanism of fluoroquinolone toxicity is still unknown. [7–10]
A recent study reported an increased incidence of ulcerative keratolysis with corneal perforation after topical fluoroquinolone treatment for microbial keratitis. These findings led us to investigate the role of various commercially available fluoroquinolone eye drop formulations on the physiological remodeling of the corneal extracellular matrix by evaluating matrix metalloproteinase expression in cornea.
Matrix metalloproteinases (MMPs) are involved in numerous physiological and pathological processes of corneal extracellular matrix remodeling and degradation. [12–14] The proteolytic properties of these enzymes may play an important role in the unidentified mechanism of ulcerative keratolysis associated with the topical use of fluoroquinolone eye drops. The MMPs can be grouped into different subclasses according to their natural substrates. We focused on two specific groups: collagenases and gelatinases; evaluating the expression of interstitial collagenase (MMP-1) and PMN collagenase (MMP-8), both of which can be secreted by corneal cells and are able to cleave corneal stromal collagens. We assessed the expression of 72-kDa gelatinase A (MMP-2) and 92-kDa gelatinase B (MMP-9) as well. These gelatinases help to degrade the basement membrane and act cooperatively with the collagenases to completely degrade interstitial corneal collagens.
Eighty female Lewis rats each weighing 250 g were first divided into two experimental groups. Each rat was prepared to produce a debrided corneal epithelium in the right eye and intact corneal epithelium in the left eye. The animals were then randomly divided into four experimental test groups of 20 rats each, as follows: Group 1 received tear drops consisting of carboxymethylcellulose sodium 0.5% (Refresh, Allergan, Irvine, CA); Group 2 received ciprofloxacin 0.3% (Ciloxan, Alcon, Fort Worth, TX); Group 3 was instilled ofloxacin 0.3% (Ocuflox, Allergan, Irvine, CA); finally, group 4 received levofloxacin 0.5%(Quixin, Santen, Napa, CA).
All of the animals were treated in accordance with the tenets of the Association for Research in Vision and Ophthalmology (ARVO) statement for the use of animals in Ophthalmic and Vision Research.
Anesthesia was achieved by intramuscular injection of 0.5 ml/kg body weight of a mixture 1:1 of 100 mg/ml ketamine and 20 mg/ml xylazine. Uniform corneal epithelial defects were created in the right eyes with the application of a filter paper disk soaked in 75% ethanol solution in the center of the tissue for 60 seconds. Immediately after the procedure, treated eyes were thoroughly irrigated with balanced salt solution. The left eye served as an intact epithelium control in each rat. Eye drops were instilled six times/day for 48 hours. Rats were sacrificed at 48 hours after initiation of treatment. The corneas from fifty six rats were removed at the scleral ring, embedded in ornithine carbamoyltransferase compound (OCT Tissue-Tek, Miles Inc., Elkhart, USA), and frozen at -80°C. Cryostat sections of 8 μm from all corneas were stained with hematoxylin and eosin, or immunohistochemically using antibodies specific for MMP-1, MMP-2, MMP-8 and MMP-9. We used six rats from each treatment group (n = 24) to perform immunoblotting and zymography studies.
Immunohistochemical staining was performed using an avidin-biotin-peroxidase complex technique. Primary antibodies consisted of polyclonal antibodies recognizing epitopes of both the pro- and active forms of MMP-1 and MMP-8 (Chemicon, Temecula, CA) as well as monoclonal antibodies against MMP-2 and MMP-9 (Oncogene, Cambridge, MA and Chemicon, Temecula, CA respectively). The primary antibodies were applied to the corneal sections and incubated at room temperature for 1 hour. After washing with TBS (20 mM Tris-HCl pH 7.5, 150 mM NaCL), a biotin-labeled secondary antibody, either goat anti-rabbit or horse anti-mouse IgG (Vector Laboratories, Burlingame, CA) was used. Finally, after incubation with the avidin-biotin-peroxidase complex (Vector Laboratories, Burlingame, CA), slides were developed in 3,3' diaminobenzidine and counterstained with 1 % methyl green in methanol. Analysis of immunostaining was performed to determine possible statistical significance between the artificial tear group and the fluoroquinolone treated groups. All samples were stained in parallel to minimize specimen variation and cell staining intensity was graded by a masked observer. A statistical calculation and significant differences in immunostaining between the treated groups and the artificial tear control group were defined as p < 0.05 by Fisher's exact test.
To quantify the metalloproteinase expression after the application of fluoroquinolone eye drops, the four test groups were analyzed by western-blot and zymography.
MMP-2 and MMP-9 levels were also assayed by zymography. Debrided (n = 24) and intact rat corneas (n = 24) from the four treatment groups were dissected and trephined (3 mm) at 48 hours and immediately cultivated in a 24-well culture dish with 500 μl of serum-free medium (MEM + minimal essential amino acid + antibiotic/antimycotic) at 37°C, 5% CO2 atmosphere for 72 hours. Each and every conditioned media aliquot was subjected to gel electrophoresis (10% SDS polyacrylamide gel containing 1 mg/ml gelatin) under nonreducing conditions. Fifteen microliters of each conditioned medium and zymography sample buffer were combined and incubated at room temperature for 5 minutes. Electrophoresis was carried out at 100 to 150 volts for 2–4 hours. The gels were washed in renaturing buffer (Bio-Rad Laboratories, Hercules, CA) for 30 minutes at room temperature, incubated with development buffer (Bio-Rad) at 37°C for 16 hours, stained for 3 hours with Coomassie Brillant Blue R-250, and destained with three changes (15, 30, 60 minutes) of destain solution (Bio-Rad Laboratories).
The levels of MMP-1 and MMP-8 in the cornea-conditioned culture medium were assessed by Western blot. The blot was probed with polyclonal antibodies against MMP-1 or MMP-8, (Chemicon, CA). Fifteen microliters of conditioned medium was mixed with electrophoresis Laemmli buffer and heated at 90°C for 5 minutes, and then kept on ice. The samples were run on 10% polyacrylamide SDS gel at 100 volts for 2 hours, and transferred to nitrocellulose membranes at 120 volts for 2 hours (Bio-Rad Richmond, CA). The nitrocellulose paper was agitated in blocking buffer at room temperature (PBS, 0.05% Tween 20, 0.5% non-fat dry milk) for 1 hour. The primary antibody (1:5000 dilution) and secondary antibody (1:2000 dilution) incubations were carried out for 1 hour respectively. After three washes with TBS-T (TBS, 0.05% Tween-20), the membranes were incubated in enhanced chemiluminescence solution (Amersham Life Science, Arlington Heights, IL) followed by exposure to chemiluminescence film for 15 seconds.
The western blots and zymograms from all treated eyes, each one in duplicate were subjected to densitometry analysis. The statistical analysis was done using one-way ANOVA test, Dunnett's multiple comparison test and Bonferroni test (SPSS, ver. 10.0 for Windows; SPSS Inc., Chicago, IL) and Microstat-Ecosoft Inc. (Indianapolis, Inc.), the values lower than 0.05 was considered statistically significant (fluoroquinolone treated groups compared to artificial tear treated group as control). The quantification of metalloproteinase values of each X-ray film and gel zymograms from all treated eyes were performed by scanning densitometry (Molecular Dynamics, Sunnyvale, CA).
Effects of Topical fluoroquinolones on Collagenase-type Metalloproteinases Immunohistochemical detection at 48 Hours
Type of eye drops
To confirm the results illustrated by immunohistochemical staining and to provide a more accurate quantitative analysis, we used western blotting and zymography techniques to study the early MMP expression after fluoroquinolone eye drop treatment. The values of each MMP bands from western blots and zymography studies made in all treated eyes were quantified by densitometry analysis and also studied statistically to indicate any significance between each fluoroquinolone treated groups and the artificial tear group (Figure 4A through 4D).
Fluoroquinolones are one class of synthetic antibacterial agents, which inhibit the bacterial topoisomerases involved in bacterial DNA replication. Since the 1980s, the U.S. Food and Drug Administration has approved several generations of fluoroquinolones. Recently, levofloxacin 0.5% solution, a third generation fluoroquinolone, was introduced as a commercial eye drop for clinical use in therapy of acute bacterial conjunctivitis. The unique structure of this drug differs from other fluoroquinolones conferring high solubility to potentially allow formulation at higher concentrations. It also extends the Gram-positive spectrum; and enhances the activity against anaerobic microbes while maintaining Gram-negative activity. Fluoroquinolones are generally well tolerated with minimal side effects when used appropriately. However, several in vitro and in vivo studies have demonstrated that both ciprofloxacin and ofloxacin eye drops significantly delay corneal wound healing.[7, 8, 16] In addition, ciprofloxacin hydrochloride 0.3% solution has demonstrated a tendency for precipitation with corneal crystal deposition, mainly in association with the pH dependent solubility of the eye drop formulation.[17, 18] The above mentioned studies suggest that the current commercially available topical fluoroquinolone agents, and their accompanying preservatives, have cytotoxic effects on corneal cells.
The metalloproteinases are potent enzymes that are capable of degrading a wide range of extracellular matrix components. Numerous studies have documented the important role of matrix metalloproteinases in the corneal wound healing process.[19, 20] The perturbation of the normal regulation of degradative processes may result in the accelerated breakdown of connective tissues and may lead to conditions such as ulcerative keratolysis. There is increasing experimental and clinical evidence that during corneal injury and inflammation, MMPs play a major role in the proteolytic processes, which can predispose the cornea to perforation. Thus, this study focuses on evaluating the expression of MMPs after the use of commercially available fluoroquinolone eye drops in order to elucidate a relationship between keratolysis, corneal perforation and the use of ophthalmic fluoroquinolone drugs as reported in previous clinical studies. The findings in the current study provide the first evidence that some undesirable effects on corneal wound healing from the use of specific fluoroquinolone eye drops (or their use in vulnerable corneal epithelium) may be secondary to the over-expression of the metalloproteinases. Furthermore, the results of our study clearly demonstrate that the commercial fluoroquinolone ophthalmic agents tested stimulate expression of corneal collagenases (MMP-1 and MMP-8) and gelatinases (MMP-2 and MMP-9) in normal eyes compared to a negative expression of MMPs in the artificial tear group. Additional studies are required to confirm the exact cellular origin of MMP-8 expressed in corneal tissue, although it is now recognized that cell types other than PMNs can express this collagenase.
Recent in vivo and in vitro studies indicate that the pathologic mechanism with fluoroquinolones may be related to significant increases of matrix-degrading proteolytic activity, inhibitory effects on cell metabolism, as well as the degenerative and ultrastructural cell changes with increased levels and interferences in the regulative pathways of several cytokines. [22–26] The clinical significance of these findings revolve around two main questions: how is the expression of these matrix metalloproteinase increased after the application of topical fluoroquinolone eye drops? and how significant are the eye drop preservatives at low concentration in stimulating MMP expression in the cornea? A new generation fluoroquinolone agent, moxifloxacin 0.5% (Vigamox, Alcon Labs, Fort Worth, TX) is commercially formulated without preservatives. Further studies addressing these important questions and explaining the cascade of factors involved in producing this increased expression of MMPs seem warranted. Physicians should be aware of the possible consequences of using fluoroquinolones for both normal and impaired corneal tissue especially with a prophylactic aim. Clinical decisions should balance safety with efficacy especially in the light of studies, such as this one, documenting the potential for corneal cytotoxicity and wound healing impairment after the topical application of commercially available fluoroquinolone drugs.
The authors would like to thanks Dr. Juan C. Muiño for providing the statistical assistance.
- Graves A, Henry M, O'Brien TP, Hwang DG, Van Buskirk A, Trousdale MD: In Vitro Susceptibilities of Bacterial Ocular Isolates to Fluoroquinolones. CORNEA. 2001, 20: 301-305. 10.1097/00003226-200104000-00012.View ArticlePubMedGoogle Scholar
- O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P: Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy of bacterial keratitis. Arch Ophthalmol. 1995, 113: 1257-1265.View ArticlePubMedGoogle Scholar
- Harrell RM: Fluoroquinolone-induced tendinopathy. What do we know?. South Med J. 1999, 92: 622-625.View ArticlePubMedGoogle Scholar
- Huston KA: Achilles tendonitis and tendon rupture due to fluoroquinolone antibiotics (Letter). N Eng J Med. 1994, 331: 748-10.1056/NEJM199409153311116.View ArticleGoogle Scholar
- Redmond AO: Risk-benefit experience of ciprofloxacin use in pediatric patients in the United Kingdom. Pediatr Infect Dis J. 1997, 16 (1): 147-9. 10.1097/00006454-199701000-00040. discussion 160–2View ArticlePubMedGoogle Scholar
- Burstein NL: Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol. 1980, 25: 15-30.View ArticlePubMedGoogle Scholar
- Cutarelli PE, Lass JH, Lazarus HM, Putman SC, Jacobs R: Topical fluoroquinolones: antimicrobial activity and in vitro corneal epithelial toxicity. Curr Eye Res. 1991, 10: 557-563.View ArticlePubMedGoogle Scholar
- Seitz B, Hayashi S, Wee WR, LaBree L, McDonnell PJ: In vitro effects of aminoglycosides and fluoroquinolones on keratocytes. Invest Ophthal Vis Sci. 1996, 37: 656-665.PubMedGoogle Scholar
- Morlet N, Minassian D, Butcher J: Ofloxacin Study Groups. Risk factors for treatment of suspected microbial keratitis. Br J Ophthalmol. 1999, 83: 1027-1031.View ArticlePubMedPubMed CentralGoogle Scholar
- Bekoe NA, Li Q, Ashraf F, O'Brien TP: Effects of ciprofloxacin, ofloxacin and gentamicin on corneal cells and wound healing. Invest Ophthalmol Vis Sci. 1999, 40: S548-Google Scholar
- Mallari PLT, McCarty DJ, Daniell M, Taylor H: Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol. 2001, 131: 131-133. 10.1016/S0002-9394(00)00642-5.View ArticlePubMedGoogle Scholar
- Massova I, Kotra LP, Fridman R, et al: Matrix metalloproteinases: structures, evolution and diversification. FASEB J. 1998, 12: 1075-1095.PubMedGoogle Scholar
- Fini ME, Parks WC, Rinehart WB, Girard MT, et al: Role of matrix metalloproteinases in failure to re-epithelialize after corneal injury. Am J Pathol. 1996, 149 (4): 1287-302.PubMedPubMed CentralGoogle Scholar
- Ye HQ, Azar DT: Statement of gelatinases A and B, and TIMPs 1 and 2 during wound healing. Invest Ophthalmol Vis Sci. 1998, 39 (6): 913-21.PubMedGoogle Scholar
- Leibowitz HM: Antibacterial effectiveness of ciprofloxacin 3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol. 1991, 112 (4 Suppl): 29S-33S.PubMedGoogle Scholar
- Moreira LB, Lee RF, Oliveira C, LaBree L, McDonnell PJ: Effect of topical fluoroquinolones on corneal re-epithelialization after excimer laser keratectomy. J Cataract Refract Surg. 1997, 23: 845-848.View ArticlePubMedGoogle Scholar
- Essepian JP, Rajpal R, O'Brien TP: Tandem scanning confocal microscopic analysis of ciprofloxacin corneal deposits in vivo. Cornea. 1995, 14: 402-407.View ArticlePubMedGoogle Scholar
- Kanellopoulos AJ, Miller F, Wittpenn JR: Deposition of topical ciprofloxacin to prevent re-epithelialization of corneal defect (Letter). Am J Ophthalmol. 1994, 117: 258-259.View ArticlePubMedGoogle Scholar
- Fini ME, Yue YJT, Sugar J: Collagenolytic / gelatinolytic metalloproteinases in normal and keratoconus corneas. Curr Eye Res. 1992, 11: 849-62.View ArticlePubMedGoogle Scholar
- Birkedal-Hansen H, Moore WG, Bodden MK, et al: Matrix metalloproteinases: a review. Crit Rev Oral Biol Med. 1993, 4 (2): 197-250.PubMedGoogle Scholar
- O'Brien TP, Li QJ, Sauerburger F, Reviglio VE, et al: The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. Ophthalmology. 2001, 108: 656-659. 10.1016/S0161-6420(00)00590-X.View ArticlePubMedGoogle Scholar
- Riesbeck K, Sigvardsson M, Leanderson T, Forsgren A: Superinduction of cytokine gene transcription by ciprofloxacin. J Immunol. 153 (1): 343-52. 1994 Jul 1Google Scholar
- Williams RJ, Attia E, Wickiewicz TL, Hannafin JA: The effect of ciprofloxacin on tendon, paratenon, and capsular fibroblast metabolism. Am J Sports Med. 2000, 28 (3): 364-9.PubMedGoogle Scholar
- Shakibaei M, Stahlmann R: Ultrastructure of Achilles tendon from rats after treatment with fleroxacin. Arch Toxicol. 2001, 75 (2): 97-102. 10.1007/s002040000203.View ArticlePubMedGoogle Scholar
- Egerbacher M, Seiberl G, Wolfesberger B, Walter I: Ciprofloxacin causes Cytoskeletal changes and detachment of human and rat chondrocytes in vitro. Arch Toxicol. 2000, 73 (10–11): 557-63. 10.1007/s002040050008.View ArticlePubMedGoogle Scholar
- Shakibaei M, Stahlmann R: Ultrastructural changes induced by the des-F(6)-quinolone garenoxacin (BMS-284756) and two fluoroquinolones in Achilles tendon from immature rats. Arch Toxicol. 2003Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2415/3/10/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.